Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Overview | Financials
Company Name Outlook Therapeutics, Inc.
Symbol OTLK
Currency USD
Price 1.42
Market Cap 33,590,952
Dividend Yield 0%
52-week-range 0.87 - 12.85
Industry Biotechnology
Sector Healthcare
CEO Mr. C. Russell Trenary III
Website https://www.outlooktherapeutics.com

An error occurred while fetching data.

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Related Stocks

Arbutus Biopharma Corporation logo

Arbutus Biopharma Corporation

ABUS

3.19 USD

Mind Medicine (MindMed) Inc. logo

Mind Medicine (MindMed) Inc.

MNMD

7.08 USD

Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

KOD

9.25 USD

Arcellx, Inc. logo

Arcellx, Inc.

ACLX

76.79 USD

Rigel Pharmaceuticals, Inc. logo

Rigel Pharmaceuticals, Inc.

RIGL

17.15 USD

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

RGC

4.77 USD

Belite Bio, Inc logo

Belite Bio, Inc

BLTE

62.82 USD

Athira Pharma, Inc. logo

Athira Pharma, Inc.

ATHA

0.513 USD

Financials

Numbers are in millions USD

Numbers are in millions USD